Journal Article Summary
The article investigates the cardiovascular disease (CVD) risk reduction associated with two obesity medications, tirzepatide and semaglutide, in individuals with obesity but without type 2 diabetes. This topic is significant because obesity is a major contributor to CVD, which accounts for a large proportion of deaths among those with high body mass index (BMI). Understanding how these medications can help reduce long-term CVD risk is crucial for improving health outcomes in the growing population of individuals affected by obesity.
The study analyzed data from the SURMOUNT-5 trial, which included participants with obesity and at least one obesity-related complication, but no prior CVD events. Participants were randomly assigned to receive either tirzepatide or semaglutide for 72 weeks. The findings revealed that tirzepatide led to a greater reduction in predicted 10-year CVD risk compared to semaglutide, with an absolute risk reduction of 2.4% for tirzepatide versus 1.4% for semaglutide. This translates to an estimated 2 million CVD events potentially preventable in the U.S. population over ten years with tirzepatide, compared to 1.15 million with semaglutide.
However, the study has limitations, including the reliance on projections rather than observed outcomes and the potential lack of generalizability due to the study's demographic makeup. Patients should discuss these findings with their healthcare providers, especially regarding the suitability of these medications for their individual health circumstances and the importance of comprehensive obesity management strategies. Understanding the broader implications of weight loss on cardiovascular health is essential for making informed treatment decisions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Mamas Mamas A, Bays Harold, Li Runjia, Upadhyay Navneet, Irani Tanya, Senyucel Cagri, Dunn Julia P, Liu-Seifert Hong. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. European Heart Journal Open 2025. DOI: 10.1093/ehjopen/oeaf117. PMID: 40980721. PMCID: PMC12448458.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
